Global impact of KRAS mutation patterns in FOLFOX treated metastatic colorectal cancer David M. Zocche et al, 2015, Frontiers in Genetics CrossRef
Pharmacogenomic Assessment of Patients with Colorectal Cancer and Potential Treatments
Gemma Bruera et al, 2020, Pharmacogenomics and Personalized Medicine CrossRef
Multidisciplinary palliation for unresectable recurrent rectal cancer: hypoxic pelvic perfusion with mitomycin C and oxaliplatin in patients progressing after systemic chemotherapy and radiotherapy, a retrospective cohort study Stefano Guadagni et al, 2019, Oncotarget CrossRef
Poorly differentiated neuroendocrine rectal carcinoma with uncommon immune-histochemical features and clinical presentation with a subcutaneous metastasis, treated with first line intensive triplet chemotherapy plus bevacizumab FIr-B/FOx regimen: an experience of multidisciplinary management in clinical practice null null et al, 2019, BMC Cancer CrossRef
KRAS, NRAS and BRAF mutations detected by next generation sequencing, and differential clinical outcome in metastatic colorectal cancer (MCRC) patients treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy Gemma Bruera et al, 2018, Oncotarget CrossRef
The prevalent KRAS exon 2 c.35 G>A mutation in metastatic colorectal cancer patients: A biomarker of worse prognosis and potential benefit of bevacizumab-containing intensive regimens? Gemma Bruera et al, 2015, Critical Reviews in Oncology/Hematology CrossRef
Toxicity Syndromes, Patient-Related Clinical Indicator of Toxicity Burden Induced by Intensive Triplet Chemotherapy-Based Regimens in Gastrointestinal Cancers With Metastatic Disease Gemma Bruera et al, 2020, Frontiers in Oncology CrossRef
Relevance of Pharmacogenomics and Multidisciplinary Management in a Young-Elderly Patient With KRAS Mutant Colorectal Cancer Treated With First-Line Aflibercept-Containing Chemotherapy Gemma Bruera et al, 2020, Frontiers in Oncology CrossRef